Combination therapy with toripalimab and lenvatinib in metastatic type 2 papillary renal cell carcinoma: a Case Report

作者：Wende Wang, Minna Chen, Wenwu Xue, De Zeng · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1591489 · 被引用次数：1 · 研究领域：Renal cell carcinoma treatment、Connective Tissue Growth Factor Research、Pancreatic and Hepatic Oncology Research

Background: Type 2 papillary renal cell carcinoma (PRCC) is an aggressive subtype of renal cell carcinoma with a poor prognosis. Diagnosis is challenging, particularly when presenting as a metastatic lung mass. This report describes a case of metastatic type 2 PRCC treated with first-line toripalimab (anti-PD-1) and lenvatinib (multikinase inhibitor), highlighting sustained clinical benefit. Case presentation: A 73-year-old man presented with cough, hemoptysis, and a large left lung mass initially misdiagnosed as primary lung cancer. Multidisciplinary re-evaluation, including immunohistochemistry (PAX8+, P504s+, also known as AMACR), confirmed metastatic type 2 PRCC. After 11 months of toripalimab (flat dose of 240 mg every 3 weeks) and lenvatinib (flat dose of 8 mg daily), serial imaging demonstrated partial response (PR) with regression of pulmonary metastases, lymphadenopathy, and obstructive pneumonia. No serious adverse events occurred. Conclusions: This case underscores the potential efficacy and tolerability of toripalimab-lenvatinib combination therapy in metastatic type 2 PRCC. Further clinical trials are warranted to validate this approach.